The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of NTX-301, an oral DNMT1 inhibitor, in patients with MDS and AML (trial in progress).
 
Pankit Vachhani
Consulting or Advisory Role - Abbvie; Amgen; Blueprint Medicines; CTI BioPharma Corp; Incyte; Jazz Pharmaceuticals; Novartis; Pfizer
Speakers' Bureau - Incyte
Research Funding - Abbvie (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); Blueprint Medicines (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Gilead/Forty Seven (Inst); Incyte (Inst); Kartos Therapeutics (Inst); Seagen (Inst); Takeda (Inst)
 
Guru Subramanian Guru Murthy
No Relationships to Disclose
 
Omer Jamy
No Relationships to Disclose
 
Kimo Bachiashvili
No Relationships to Disclose
 
Sravanti Rangaraju
No Relationships to Disclose
 
Tonya Cole
No Relationships to Disclose
 
Corinne E Augelli-Szafran
No Relationships to Disclose
 
Rebecca J Boohaker
No Relationships to Disclose
 
Omar Moukha-Chafiq
No Relationships to Disclose
 
Lynae J Hanks
No Relationships to Disclose
 
Karr Stinson
No Relationships to Disclose
 
Doo Young Jung
Employment - Pinotbio
Leadership - Pinotbio
Stock and Other Ownership Interests - Pinotbio
 
Ehab L. Atallah
Consulting or Advisory Role - Abbvie/Genentech; Bristol-Myers Squibb; Jazz Pharmaceuticals; Novartis; Pfizer; Syndax; Takeda
Speakers' Bureau - Abbvie; Celgene; Jazz Pharmaceuticals; Novartis
Research Funding - Novartis (Inst); Takeda (Inst)
 
Ravi Bhatia
No Relationships to Disclose